Author:
Marshall Catherine H.,Sokolova Alexandra O.,McNatty Andrea L.,Cheng Heather H.,Eisenberger Mario A.,Bryce Alan H.,Schweizer Michael T.,Antonarakis Emmanuel S.
Funder
National Institutes of Health Cancer Center
Pacific Northwest Prostate Cancer SPORE
Department of Defense
Patrick C. Walsh Research Fund
Institute for Prostate Cancer Research and Prostate Cancer Foundation Awards
Reference20 articles.
1. US Food & Drug Administration. FDA approves olaparib for germline BRCA-mutated metastatic breast cancer. www.fda.gov/drugs/informationondrugs/approveddrugs/ucm592357.htm.
2. Mismatch-repair deficiency predicts response of solid tumors to PD-1 blockade;Le;Science,2017
3. The long tail of oncogenic drivers in prostate cancer;Armenia;Nat Genet,2018
4. Press release. Lynparza (olaparib) granted breakthrough therapy designation by US FDA for treatment of BRCA1/2 or ATM gene mutated metastatic castration resistant prostate cancer;AstraZeneca,2016
5. DNA-repair defects and olaparib in metastatic prostate cancer;Mateo;N Engl J Med,2015